DOAC-Associated Bleeding in Adults

Clinical Overview

Direct oral anticoagulants (DOACs) have revolutionized anticoagulation therapy, offering predictable pharmacokinetics without routine monitoring. However, DOAC-associated bleeding remains a critical clinical challenge, with major bleeding rates of 2-4% annually and case fatality rates approaching 10-13% for intracranial hemorrhage.

Four DOAC Classes:

• Direct thrombin inhibitor: Dabigatran (Pradaxa)
• Factor Xa inhibitors: Rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), betrixaban (Bevyxxa)

Key Clinical Principle: DOAC bleeding management differs fundamentally from warfarin reversal. Specific reversal agents (idarucizumab for dabigatran, andexanet alfa for factor Xa inhibitors) provide targeted, immediate reversal but require prompt recognition of the specific DOAC involved.

Evidence Level: Recommendations based on randomized controlled trials (RE-VERSE AD, ANNEXA-4), large observational cohorts, and expert consensus (2020 ACC/2019 Anticoagulation Forum).

---

Epidemiology

Incidence and Prevalence

DOAC Utilization (2023-2024 Data):

• Over 15 million patients worldwide on DOACs
• 65% prescribed for atrial fibrillation stroke prevention
• 25% for venous thromboembolism treatment/prevention
• 10% for other indications (ACS, post-orthopedic surgery)

Bleeding Event Rates (Meta-analysis, n=94,656):

• Major bleeding: 2.1-3.6% per year (vs. 3.4-3.9% with warfarin)
• Intracranial hemorrhage: 0.2-0.5% per year (50% lower than warfarin)
• Fatal bleeding: 0.2% per year
• GI bleeding: 1.2-1.5% per year (higher with rivaroxaban 20mg vs. apixaban 5mg)

Clinical Impact:

• Major bleeding increases mortality risk 5-fold (HR 5.0, 95% CI 3.7-6.7)
• ICH case fatality rate: 45-52% at 90 days
• Major GI bleeding requiring transfusion: 30-day mortality 5-7%

Risk Factors for DOAC Bleeding

Patient-Related (HAS-BLED Score Components):

Drug-Related Factors:

• Dabigatran: Higher GI bleeding than warfarin (RR 1.5, 95% CI 1.2-1.9), especially at 150mg BID
• Rivaroxaban: Highest GI bleeding among DOACs (20mg once daily formulation)
• Apixaban: Lowest major bleeding rates (ARISTOTLE trial: 2.1% vs. 3.1% warfarin)
• Edoxaban: GI bleeding risk varies by dose (60mg vs. 30mg)

Drug Interactions Increasing Bleeding Risk:

---

Pathophysiology

DOAC Mechanisms of Action

Dabigatran (Direct Thrombin Inhibitor):

• Prodrug (dabigatran etexilate) converted to active dabigatran
• Binds directly to thrombin active site (both free and clot-bound)
• Prevents fibrinogen → fibrin conversion
• Competitive, reversible inhibition
• Pharmacokinetics:
  • "Bioavailability: 3-7% (poor absorption, improved by acidic environment)"
  • "Peak levels: 0.5-2 hours (fasting), 2-3 hours (fed)"
  • "Half-life: 12-17 hours (normal renal function), 28-34 hours (CrCl less than 30)"
  • "Renal excretion: 80% (contraindicated if CrCl less than 30, requires dose reduction if CrCl 30-50)"
  • "Protein binding: 35% (dialyzable)"

Factor Xa Inhibitors (Rivaroxaban, Apixaban, Edoxaban):

• Direct, selective inhibition of factor Xa active site
• Block both free and prothrombinase-bound factor Xa
• Prevent prothrombin → thrombin conversion
• Rivaroxaban:
  • "Bioavailability: 80-100% (10mg), 66% (20mg requires food)"
  • "Peak: 2-4 hours"
  • "Half-life: 5-9 hours (young), 11-13 hours (elderly)"
  • "Renal excretion: 33% (avoid if CrCl less than 30)"
  • "Hepatic metabolism: CYP3A4/5, CYP2J2"
  • "Protein binding: 92-95% (not dialyzable)"
• Apixaban:
  • "Bioavailability: ~50%"
  • "Peak: 1-3 hours"
  • "Half-life: 8-15 hours"
  • "Renal excretion: 25%"
  • "Protein binding: 87% (not dialyzable)"
• Edoxaban:
  • "Bioavailability: 62%"
  • "Peak: 1-2 hours"
  • "Half-life: 10-14 hours"
  • "Renal excretion: 50%"
  • "Protein binding: 55% (not dialyzable)"

Hemostatic Alterations in DOAC Bleeding

Normal Hemostatic Response:

1. Vascular injury → platelet adhesion (vWF, GP Ib/IX)
2. Platelet activation → aggregation (GP IIb/IIIa)
3. Tissue factor exposure → factor VIIa → factor X activation
4. Factor Xa + Va (prothrombinase complex) → thrombin generation
5. Thrombin → fibrinogen cleavage → fibrin mesh → stable clot

DOAC-Impaired Hemostasis:

• Dabigatran: ↓ thrombin → ↓ fibrin formation, ↓ factor XIII activation, ↓ platelet activation
• Factor Xa inhibitors: ↓ prothrombinase → ↓ thrombin generation (90% reduction at therapeutic levels)

Laboratory Effects:

Critical Point: Normal aPTT/PT does NOT exclude therapeutic DOAC levels. Drug-specific assays (dilute thrombin time for dabigatran, anti-Xa for factor Xa inhibitors calibrated to specific DOAC) required for quantification.

Reversal Agent Mechanisms

Idarucizumab (Praxbind) - Dabigatran-Specific:

• Humanized monoclonal antibody fragment (Fab)
• Binds dabigatran with 350-fold higher affinity than thrombin
• Immediately neutralizes free and bound dabigatran
• Stoichiometric binding: 1g idarucizumab neutralizes 90mg dabigatran
• Standard dose: 5g IV (two 2.5g vials) sufficient for peak therapeutic levels
• No procoagulant activity
• Renal excretion (half-life 45 minutes, but reversal sustained 24 hours)
• RE-VERSE AD trial: 89% immediate, complete reversal in 503 patients

Andexanet Alfa (Andexxa) - Factor Xa Inhibitor-Specific:

• Modified recombinant factor Xa (inactive decoy)
• Lacks enzymatic activity (Gla domain deleted, Ser to Ala substitution)
• Binds and sequesters rivaroxaban, apixaban, edoxaban (also LMWH, fondaparinux)
• Acts as "decoy" to restore native factor Xa availability
• Dosing: Based on last DOAC dose and timing
  • "Low dose: 400mg bolus + 4mg/min × 120 min (480mg total)"
  • "High dose: 800mg bolus + 8mg/min × 120 min (960mg total)"
• Challenge: Short half-life (5-7 hours) → rebound anticoagulation if DOAC levels persist
• ANNEXA-4 trial: 82% excellent/good hemostasis in 352 patients
• Caution: 10% thrombotic event rate at 30 days (ischemic stroke, MI, DVT)

4-Factor Prothrombin Complex Concentrate (4F-PCC, Kcentra):

• Contains factors II, VII, IX, X + proteins C and S
• Non-specific reversal: bypasses factor Xa inhibition by providing downstream factors
• Dose: 25-50 units/kg IV (based on factor IX content)
• Evidence: Case series show variable efficacy
  • Reduces anti-Xa levels but may not normalize hemostasis
  • No large RCT for DOAC reversal (approved for warfarin)
  • 0.9-1.8% thrombotic complication rate
• Use when andexanet unavailable or cost-prohibitive

---

Clinical Presentation

Bleeding Severity Classification

International Society on Thrombosis and Haemostasis (ISTH) Major Bleeding Criteria:

1. Fatal bleeding
2. Symptomatic bleeding in critical area/organ:
   • Intracranial (ICH, SAH, SDH, epidural)
   • Intraspinal (spinal hematoma with cord compression)
   • Intraocular (vitreous hemorrhage with vision loss)
   • Pericardial (cardiac tamponade)
   • Intra-articular (hemarthrosis)
   • Intramuscular with compartment syndrome
   • Retroperitoneal
3. Bleeding causing hemoglobin fall ≥2 g/dL
4. Bleeding requiring transfusion ≥2 units pRBCs

Clinically Relevant Non-Major Bleeding (CRNMB):

• Requires medical intervention (ED visit, hospitalization)
• Does not meet ISTH major bleeding criteria
• Examples: Epistaxis requiring packing, GI bleeding without transfusion, hematuria requiring catheter irrigation

Minor Bleeding:

• Does not meet major or CRNMB criteria
• Managed with local measures
• Examples: Bruising, minor gum bleeding, small hematomas

Life-Threatening Bleeding Presentations

Intracranial Hemorrhage (ICH) - Highest Mortality:

• Incidence: 0.3-0.6% per year on DOACs (vs. 0.7-1.0% on warfarin)
• Clinical features:
  • Altered mental status (GCS less than 15)
  • Focal neurological deficits (hemiparesis, aphasia, neglect)
  • Headache (sudden, severe, "worst of life")
  • Nausea/vomiting (especially posterior fossa bleeds)
  • Seizures (10-15% of ICH patients)
  • "Cushing's triad (late sign: hypertension, bradycardia, irregular respirations)"
• Subtypes:
  • "Intracerebral hemorrhage (ICH): 60-70% (basal ganglia, thalamus, pons most common)"
  • "Subdural hematoma (SDH): 20-30% (often traumatic, elderly with atrophy)"
  • "Subarachnoid hemorrhage (SAH): 5-10% (thunderclap headache, meningismus)"
  • "Epidural hematoma: less than 5% (usually traumatic with skull fracture)"
• Prognosis: 90-day mortality 45-52%, functional independence less than 30%
• Hematoma expansion: Occurs in 30-40% within 24 hours → urgent reversal critical

Spinal Epidural Hematoma:

• Risk factors: Neuraxial anesthesia/analgesia within 24 hours, spinal trauma, spinal procedures
• Presentation: Acute back pain → radicular pain → paraparesis/paraplegia → bladder/bowel dysfunction
• Window for intervention: less than 8 hours for neurological recovery
• Diagnosis: Urgent MRI spine (T2 hyperintense epidural collection)

Retroperitoneal Hemorrhage:

• Presentation: Flank/back pain, abdominal distension, hypotension, psoas sign
• Grey Turner sign: Flank ecchymosis (late finding)
• Cullen sign: Periumbilical ecchymosis (rare)
• Diagnosis: CT abdomen/pelvis with IV contrast (active extravasation if present)
• Complications: Abdominal compartment syndrome (bladder pressure > 20 mmHg), femoral nerve compression

Airway-Threatening Hemorrhage:

• Retropharyngeal/parapharyngeal hematoma: Dysphagia, dyspnea, stridor, neck swelling
• Ludwig's angina: Sublingual/submandibular bleeding (rare)
• Management: Secure airway EARLY (intubation may become impossible), reversal, ENT consult

GI Bleeding with Hemodynamic Instability:

• Upper GI: Hematemesis (coffee-ground or bright red), melena, hypotension
• Lower GI: Hematochezia (bright red blood per rectum), clots
• Occult: Unexplained hemoglobin drop, syncope, shock
• Risk stratification:
  • "Glasgow-Blatchford Score (GBS): ≥12 indicates high risk (SBP, HR, Hgb, melena, syncope)"
  • "AIMS65 Score: ≥2 predicts inpatient mortality"
• DOAC-specific: Rivaroxaban associated with higher upper GI bleeding vs. apixaban

Major Bleeding (Non-Life-Threatening)

Upper GI Bleeding (Stable):

• Common sources: Peptic ulcer (40%), erosive gastritis/duodenitis (25%), esophageal varices (10%), Mallory-Weiss tear (5-10%), angiodysplasia (5%)
• Presentation: Melena, hematemesis, epigastric pain
• Endoscopy: Within 12-24 hours (stable), within 12 hours (high-risk stigmata)

Lower GI Bleeding:

• Common sources: Diverticulosis (40%), angiodysplasia (30%), ischemic colitis (10%), hemorrhoids (10%)
• Presentation: Hematochezia, maroon stools
• Colonoscopy: After adequate bowel prep (if hemodynamically stable)

Genitourinary Bleeding:

• Hematuria: Gross hematuria (visible) vs. microscopic
• Sources: BPH, cystitis, nephrolithiasis, malignancy, traumatic catheterization
• Imaging: CT urogram (non-contrast + contrast + delayed for GU tract)

Hemoptysis:

• Massive: > 200-600 mL/24 hours (definitions vary)
• Sources: Bronchitis, pneumonia, PE, malignancy, bronchiectasis
• Management: Patient positioning (bleeding side down), bronchoscopy, interventional radiology

Soft Tissue Hematomas:

• Muscle: Thigh, calf, psoas (retroperitoneal)
• Compartment syndrome: Pain out of proportion, tense compartment, sensory/motor deficits
• Femoral nerve palsy: Psoas hematoma compressing femoral nerve (hip flexion weakness, anterior thigh numbness)

---

Red Flags (Life-Threatening Presentations)

Special Consideration - Intracranial Hemorrhage:

• Hematoma expansion: Occurs in 33% of patients within 24 hours
• Predictors of expansion: Anticoagulation, irregular hematoma shape, "spot sign" on CTA, short time from symptom onset
• Reversal urgency: Every 30-minute delay increases mortality by 18% (observational data)

---

Differential Diagnosis

Bleeding in Anticoagulated Patients

DOAC-Related Bleeding vs. Structural Lesion:

• DOACs unmask underlying pathology (e.g., occult GI malignancy, cerebral amyloid angiopathy)
• Always investigate source even if bleeding attributed to anticoagulation
• Red flag: Recurrent bleeding at same site → high suspicion for structural lesion

Other Causes of Coagulopathy:

Drug-Drug Interactions Mimicking DOAC Overdose:

• P-gp/CYP3A4 inhibitors: Verapamil, dronedarone, azole antifungals → ↑ DOAC levels
• Antiplatelet agents: DAPT + DOAC → additive bleeding risk without abnormal coags

Trauma vs. Spontaneous Bleeding:

• Trauma: Even minor trauma (fall from standing) can cause ICH/SDH in anticoagulated patients
• Spontaneous: No identifiable trigger (suggests higher bleeding tendency or underlying lesion)

---

Diagnostic Approach

Initial Assessment (First 15 Minutes)

ABCDE Survey:

• Airway: Assess for airway hematoma (stridor, dysphagia, neck swelling)
• Breathing: Respiratory distress from hemothorax, pulmonary hemorrhage
• Circulation: Vital signs (BP, HR), signs of shock (cool extremities, delayed cap refill, altered mentation)
• Disability: GCS, focal neurological deficits, pupillary exam
• Exposure: Identify bleeding source (external bleeding, ecchymoses, abdominal distension)

Critical History (SAMPLE):

• Which DOAC? Dabigatran vs. rivaroxaban vs. apixaban vs. edoxaban (determines reversal strategy)
• Dose and timing: When was last dose? (e.g., dabigatran 110mg vs. 150mg BID, rivaroxaban 15mg vs. 20mg daily)
• Indication: AF, VTE, other (determines if/when to resume anticoagulation)
• Renal function: Known CKD? Recent creatinine? (affects DOAC clearance)
• Concomitant medications: Antiplatelet agents? P-gp/CYP3A4 inhibitors?
• Prior bleeding: Previous bleeds on anticoagulation?
• Trauma: Recent fall, head trauma, procedures?

Medication Verification:

• Confirm DOAC from medication list, patient/family, pharmacy records
• Do NOT assume based on indication alone (many patients switched between agents)

Laboratory Investigations

Immediate Labs (Stat):

DOAC-Specific Assays (if available, send STAT):

Point-of-Care Testing:

• Thromboelastography (TEG) or Rotational thromboelastometry (ROTEM): May detect DOAC effect but not widely validated
• Viscoelastic tests: Helpful in massive transfusion scenarios

Critical Pitfall: Standard PT/aPTT are unreliable for excluding therapeutic DOAC levels. Apixaban may have minimal effect on PT; dabigatran at therapeutic levels may have normal aPTT in some assays.

Imaging Studies

Intracranial Hemorrhage Suspected:

• Non-contrast CT head: First-line, rapid (less than 5 min scan), 95% sensitive for acute ICH
  • Hyperdense (bright) blood in acute phase
  • Identify location, volume (ABC/2 method), midline shift, herniation
• CT angiography (CTA) head: "Spot sign" predicts hematoma expansion (contrast extravasation within hematoma)
• MRI brain: More sensitive for small bleeds, posterior fossa, microbleeds (GRE/SWI sequences)

Spinal Hemorrhage Suspected:

• MRI spine (with contrast): Gold standard for epidural hematoma
  • T2 hyperintense epidural collection
  • Cord compression, signal change within cord
• CT myelography: If MRI contraindicated (e.g., pacemaker)

GI Bleeding:

• CT abdomen/pelvis with IV contrast: Identifies active extravasation (if > 0.5 mL/min), mass lesions
• CT angiography: Higher sensitivity for active bleeding (arterial phase)
• Endoscopy: Upper (EGD) or lower (colonoscopy) based on presentation
  • "High-risk stigmata: Active bleeding, visible vessel, adherent clot → endoscopic hemostasis"

Retroperitoneal Bleeding:

• CT abdomen/pelvis with IV contrast: Identifies hematoma, active extravasation
• Angiography: If active extravasation identified, consider IR embolization

Chest:

• CT chest with IV contrast: Hemothorax, pulmonary hemorrhage, hemopericardium

Ultrasound (Point-of-Care):

• FAST exam: Pericardial effusion/tamponade, intraperitoneal free fluid (blood)
• Echocardiography: Pericardial effusion with diastolic collapse (tamponade)

Timing Considerations

Last DOAC Dose → Expected Drug Effect:

Renal Impairment Adjustments (Dabigatran):

• CrCl less than 30: Half-life prolonged to 28-34 hours → drug effect may persist > 48 hours
• CrCl 30-50: Half-life 18-22 hours → adjust timing expectations

---

Treatment

Immediate Resuscitation (All Patients)

ABCDE Approach:

A - Airway:

• Secure airway if:
  • GCS less than 8
  • Expanding neck hematoma
  • Massive hematemesis with aspiration risk
• Consider awake fiberoptic intubation if airway hematoma (neck hematoma may worsen with paralysis/sedation)

B - Breathing:

• Supplemental O₂ to maintain SpO₂ > 94%
• Mechanical ventilation if needed (hemothorax, pulmonary hemorrhage, ICH with ↓ GCS)

C - Circulation:

1. Large-bore IV access (two 18G or larger peripheral IVs)
   - Central line if peripheral access inadequate
   - Avoid femoral lines if retroperitoneal bleed suspected

2. Aggressive crystalloid resuscitation (balanced crystalloid)
   - Initial bolus 500-1000 mL
   - Target SBP 90-100 mmHg (permissive hypotension if ongoing bleeding)
   - Avoid over-resuscitation (↑ bleeding risk)

3. Activate massive transfusion protocol if:
   - Hemodynamic instability despite 2L crystalloid
   - Suspicion of > 4 units pRBC requirement
   - Active exsanguinating hemorrhage

4. Transfusion strategy:
   - pRBCs : FFP : Platelets = 1:1:1 (trauma ratios)
   - Target Hgb > 7 g/dL (> 8-9 g/dL if ongoing bleeding or CAD)
   - Target platelets > 50,000/μL (> 100,000 if ICH or neurosurgery planned)
   - Target fibrinogen > 150 mg/dL (cryoprecipitate if less than 150)

5. Tranexamic acid (TXA):
   - 1g IV over 10 min, then 1g IV over 8 hours
   - Evidence: CRASH-2 (trauma), WOMAN (PPH), limited data in DOAC bleeding
   - Consider in massive bleeding (especially trauma-related)
   - Caution: Thrombotic risk, seizure risk (ICH)

D - Disability:

• Serial neurological exams (GCS, pupils, motor)
• If ICH: Avoid hypotension (target SBP 140-160 mmHg), avoid hyperglycemia

E - Exposure:

• Identify bleeding source
• Direct pressure to compressible bleeding sites

Hold Anticoagulation:

• Discontinue DOAC immediately
• Do NOT give next dose until bleeding controlled and risk/benefit reassessed

Specific Reversal Strategies

DABIGATRAN REVERSAL:

Idarucizumab (Praxbind) - First-Line, Specific Antidote:

Dose: 5g IV (two 2.5g/50mL vials)

Administration:
- Give as two consecutive IV boluses (2.5g each, 5-10 min apart)
  OR
- Give as continuous infusion (both vials over 15 min)

Onset: Immediate (within minutes)
Duration: Sustained reversal for 24 hours
Repeat dosing: Rarely needed; consider if:
  - Rebleeding occurs
  - Life-threatening bleeding persists
  - Large dabigatran ingestion (less than 2 hours ago, ongoing absorption)

Monitoring:
- dTT or ECT normalize within 4 hours (if initially elevated)
- aPTT may remain elevated if other factors present

Evidence:
- RE-VERSE AD trial (Pollack et al., NEJM 2017):
  - 503 patients with dabigatran-associated bleeding or urgent surgery
  - 89% complete reversal within 4 hours (median 11.4 min)
  - "Hemostatic efficacy: 92% in surgical patients, 68% in bleeding patients"
  - "Thrombotic events: 4.8% at 90 days (many due to underlying indication)"

Indications:
- Life-threatening bleeding (ICH, major hemorrhage)
- Need for urgent surgery/procedure (less than 8 hours)

Availability: Hospital formulary (expensive, ~$18,000-20,000 per dose)

Hemodialysis - Adjunct for Dabigatran:

Efficacy:
- Removes 50-60% of dabigatran in 4 hours
- 35-40% in 2 hours
- Protein binding 35% → dialyzable

Indications:
- Idarucizumab not available AND
- Severe renal impairment (CrCl less than 30) with dabigatran accumulation
- Massive dabigatran overdose

Limitations:
- Requires 2-4 hours for significant removal
- Rebound effect (redistribution from tissues)
- Not practical for immediate life-threatening bleeding

Evidence: Case series, pharmacokinetic studies (no RCTs)

FACTOR Xa INHIBITOR REVERSAL (Rivaroxaban, Apixaban, Edoxaban):

Andexanet Alfa (Andexxa) - First-Line, Specific Antidote:

Dosing Based on Last DOAC Dose and Timing:

LOW DOSE:
- Rivaroxaban ≤10mg taken less than 8 hours ago OR > 8 hours ago
- Apixaban ≤5mg taken > 8 hours ago
- Unknown DOAC/dose/timing (if necessary to treat)

Regimen:
- 400mg IV bolus (30 mg/min over 13-15 min)
- Followed by 4 mg/min continuous infusion × 120 minutes (480mg)
- TOTAL: 880mg

HIGH DOSE:
- Rivaroxaban > 10mg taken less than 8 hours ago
- Apixaban > 5mg taken less than 8 hours ago OR any dose less than 8 hours ago
- Edoxaban (any dose, any timing)
- Enoxaparin (LMWH)

Regimen:
- 800mg IV bolus (30 mg/min over 26-30 min)
- Followed by 8 mg/min continuous infusion × 120 minutes (960mg)
- TOTAL: 1760mg

Onset: Immediate reduction in anti-Xa activity (median 89% reduction)
Duration: 2 hours (infusion duration); effect wanes after infusion stops

Monitoring:
- Anti-Xa levels (if available): Nadir at end of bolus, rise after infusion
- Clinical hemostasis

Evidence:
- ANNEXA-4 trial (Connolly et al., NEJM 2019):
  - 352 patients with factor Xa inhibitor-associated major bleeding
  - 82% achieved excellent/good hemostasis at 12 hours
  - "Median anti-Xa reduction: 92% (rivaroxaban), 93% (apixaban)"
  - "Thrombotic events: 10% at 30 days (ischemic stroke 6%, MI 2%, VTE 6%)"
  - 30-day mortality: 14% (primarily bleeding-related)

Rebound Anticoagulation:
- Anti-Xa levels rise 1-3 hours after infusion stops
- Mechanism: Andexanet cleared faster than DOAC
- Clinical significance unclear (no proven increased rebleeding vs. PCC)

Indications:
- Life-threatening bleeding (ICH, major hemorrhage)
- Uncontrolled bleeding despite supportive measures

Contraindications:
- Known hypersensitivity
- None absolute if life-threatening bleeding

Availability: Limited (very expensive, ~$50,000 per dose)
Cost: Often requires pharmacy approval, institutional protocols

4-Factor Prothrombin Complex Concentrate (4F-PCC, Kcentra) - Alternative:

Dose: 25-50 units/kg IV (based on factor IX content)
- Most institutions use 50 units/kg for major bleeding
- Max dose typically 5000 units

Example Dosing:
- 70 kg patient: 50 units/kg × 70 = 3500 units
- Round to nearest vial size (500-unit vials): 3500 units

Administration:
- Reconstitute per manufacturer instructions
- Infuse at ≤4 units/kg/min (too rapid → thrombosis risk)
- Typical infusion time: 20-30 minutes

Mechanism:
- Provides factors II, VII, IX, X → bypasses Xa inhibition
- Does NOT directly reverse factor Xa inhibitors (no antidote mechanism)
- Restores thrombin generation capacity

Evidence:
- No large RCT for DOAC reversal (approved for warfarin reversal)
- Case series/retrospective cohorts:
  - Variable hemostatic efficacy (50-80%)
  - May reduce anti-Xa levels modestly (not consistently)
  - "Thrombotic events: 0.9-1.8% (VTE, stroke)"
- 2019 Anticoagulation Forum Guidance: "May consider" if andexanet unavailable

Indications:
- Life-threatening factor Xa inhibitor bleeding AND andexanet unavailable/delayed
- Cost considerations (4F-PCC ~$3,000-5,000 vs. andexanet ~$50,000)

Monitoring:
- Clinical hemostasis (no specific lab test to guide dosing)
- Anti-Xa levels do NOT reliably decrease

Thrombotic Risk:
- 0.9-1.8% symptomatic VTE
- Higher risk if prothrombotic conditions (malignancy, recent surgery)

3-Factor PCC: NOT recommended (lacks factor VII, inferior to 4F-PCC)

Activated Prothrombin Complex (aPCC, FEIBA): Limited data, reserved for refractory bleeding

Fresh Frozen Plasma (FFP): NOT effective (insufficient factor concentrations, large volumes)

Adjunctive Hemostatic Measures

Activated Charcoal:

Indications:
- DOAC ingestion less than 2 hours ago
- Patient able to protect airway (GCS ≥13)
- No contraindications (bowel obstruction, perforation, unprotected airway)

Dose: 50g PO (or via NG tube if in place)

Efficacy:
- Reduces DOAC absorption by ~50% if given within 2 hours
- No benefit if > 2-3 hours post-ingestion (DOACs absorbed)

Evidence: Pharmacokinetic studies (no clinical outcomes data)

Tranexamic Acid (TXA):

Dose:
- 1g IV over 10 min (loading)
- Followed by 1g IV over 8 hours (maintenance)

OR (trauma protocols):
- 1g IV bolus, then 1g over 8 hours (CRASH-2 regimen)

Mechanism: Inhibits plasminogen activation → prevents fibrinolysis

Evidence in DOAC Bleeding:
- No RCTs specifically for DOAC bleeding
- Extrapolated from trauma (CRASH-2), PPH (WOMAN), other bleeding
- CRASH-2: 1.5% absolute reduction in death from bleeding (trauma)

Indications (consider in DOAC bleeding):
- Massive bleeding requiring transfusion
- Trauma-related bleeding
- Ongoing bleeding despite reversal

Contraindications:
- Known thromboembolic event in past 24 hours
- Seizure history (especially ICH - TXA may ↑ seizure risk)
- DIC

Timing: Most effective if given within 3 hours of bleeding onset (CRASH-2)

Desmopressin (DDAVP):

Dose: 0.3 μg/kg IV (max 20 μg)

Mechanism: Releases vWF and factor VIII from endothelial stores

Indications:
- Uremia-associated platelet dysfunction (+ anticoagulation)
- Mild hemophilia A or von Willebrand disease (+ DOAC bleeding)

NOT effective for: DOAC reversal alone (no direct mechanism)

Recombinant Factor VIIa (rFVIIa, NovoSeven):

Dose: 90 μg/kg IV (off-label for DOAC bleeding)

Evidence:
- Case reports/small series for DOAC bleeding
- High thrombotic risk (arterial events 5-10%)
- NOT recommended by guidelines (reserve for refractory bleeding unresponsive to other measures)

Indications (last resort):
- Life-threatening bleeding unresponsive to reversal agents, PCC, transfusion
- Multidisciplinary decision (hematology, ICU)

Transfusion Thresholds and Targets

Red Blood Cells (pRBCs):

• Restrictive strategy (most patients): Transfuse if Hgb less than 7 g/dL
• Liberal strategy (active bleeding, CAD, ICH): Transfuse if Hgb less than 8-9 g/dL
• Target: Hgb 7-9 g/dL (not > 10 g/dL unless symptomatic anemia)

Platelets:

• Major bleeding: Transfuse if less than 50,000/μL → Target > 50,000/μL
• ICH or neurosurgery planned: Transfuse if less than 100,000/μL → Target > 100,000/μL
• Minor bleeding: Transfuse if less than 20,000-30,000/μL (depends on bleeding site)

Fresh Frozen Plasma (FFP):

• Indications: Massive transfusion protocol (1:1:1 ratio), fibrinogen less than 150 mg/dL (if cryoprecipitate unavailable)
• Dose: 10-15 mL/kg (typically 4 units for 70 kg patient)
• NOT effective for DOAC reversal alone (insufficient factor concentrations)

Cryoprecipitate:

• Indications: Fibrinogen less than 150 mg/dL
• Dose: 10 units (1 unit raises fibrinogen ~5-10 mg/dL)
• Target: Fibrinogen > 150 mg/dL (> 200 mg/dL if massive bleeding)

Massive Transfusion Protocol (MTP):

• Trigger: Hemorrhagic shock, anticipated > 4 units pRBCs in 1 hour
• Ratio: pRBCs : FFP : Platelets = 1:1:1 (or 6:4:1 per round)
• Example: Round 1 = 6 pRBCs, 4 FFP, 1 platelet pool (apheresis or 6-pack)

Bleeding Site-Specific Management

Intracranial Hemorrhage (ICH):

1. Immediate reversal (idarucizumab or andexanet alfa)
   - Goal: Reverse anticoagulation less than 30-60 min from arrival

2. Blood pressure control:
   - Target SBP 140-160 mmHg (avoid hypotension and excessive reduction)
   - IV labetalol 10-20mg boluses
   - IV nicardipine infusion 5 mg/hr (titrate to target)
   - Avoid nitroprusside (↑ ICP from cerebral vasodilation)

3. Neurosurgical consultation (STAT):
   - Indications for surgery:
     - Cerebellar hemorrhage > 3 cm with brainstem compression or hydrocephalus
     - Lobar ICH with deterioration
     - Subdural/epidural hematoma with midline shift
   - Most supratentorial ICH managed medically

4. ICP management (if indicated):
   - Head of bed 30°
   - Avoid hypoxia, hypercapnia
   - Osmotic therapy: Mannitol 0.5-1 g/kg IV or hypertonic saline (3% NaCl)
   - Consider EVD if hydrocephalus

5. Seizure prophylaxis: NOT routine (unless seizure witnessed)

6. Avoid: Corticosteroids (no benefit), platelet transfusion (unless thrombocytopenic)

7. Monitoring: Neuro ICU, serial CT scans (24 hours, PRN if deterioration)

Evidence:
- INTERACT2, ATACH-2: Intensive BP lowering (SBP less than 140) did NOT improve outcomes
- AHA/ASA 2015 ICH Guidelines: SBP 140-160 mmHg reasonable

Gastrointestinal Bleeding:

Upper GI Bleeding:
1. Risk stratification: Glasgow-Blatchford Score (GBS), Rockall Score
2. Reversal agent (if life-threatening or major bleeding)
3. IV PPI: Pantoprazole 80mg bolus, then 8 mg/hr infusion (if suspected peptic ulcer)
4. Endoscopy:
   - Urgent (less than 12 hours): Hemodynamic instability, suspected variceal bleed
   - Early (less than 24 hours): Stable high-risk features (GBS ≥12)
5. Octreotide: 50 μg bolus, then 50 μg/hr infusion (if variceal bleeding suspected)

Lower GI Bleeding:
1. Reversal agent (if life-threatening or major bleeding)
2. Colonoscopy after bowel prep (if hemodynamically stable)
3. CT angiography: If ongoing bleeding, unable to prep for colonoscopy
4. Interventional radiology: Embolization if extravasation identified on CTA
5. Surgery: If uncontrolled bleeding despite endoscopic/IR interventions

Retroperitoneal Hemorrhage:

1. Reversal agent
2. Avoid pelvic/femoral access (may worsen hematoma)
3. CT angiography: Identify active extravasation
4. Interventional radiology: Embolization if extravasation present (success ~80-90%)
5. Surgery: If IR fails or not available (rare)
6. Monitor for abdominal compartment syndrome: Serial bladder pressures
7. Femoral nerve palsy: Physical therapy, gradual recovery (weeks-months)

Spinal Epidural Hematoma:

1. Immediate reversal (idarucizumab or andexanet alfa)
2. Emergent MRI spine (confirm diagnosis)
3. Neurosurgical consultation STAT
4. Decompressive laminectomy: If less than 8 hours from symptom onset and neurological deficit
5. Prognosis: Recovery depends on severity of deficit and time to decompression

Airway Hematoma:

1. Secure airway EARLY (before complete obstruction)
   - Consider awake fiberoptic intubation
   - Surgical airway (cricothyrotomy) if unable to intubate
2. Immediate reversal
3. ENT consultation
4. Avoid blind intubation attempts (may worsen bleeding)

When to Resume Anticoagulation

General Principles:

• Risk-benefit assessment: Balance thrombotic risk vs. rebleeding risk
• Multidisciplinary discussion: Hematology, neurology/cardiology, primary team

Timing Guidelines (ACC Expert Consensus 2020):

Factors Favoring EARLY Resumption (within days):

• Very high thrombotic risk:
  • Mechanical heart valve (prosthetic mitral/aortic)
  • AF with CHA₂DS₂-VASc ≥5-6
  • Recent VTE (less than 3 months ago)
  • Recurrent VTE despite anticoagulation
• Reversible bleeding trigger identified and corrected

Factors Favoring DELAYED or NO Resumption:

• High rebleeding risk:
  • Cerebral amyloid angiopathy
  • GI malignancy (unresected)
  • Severe uncontrolled hypertension
  • Prior major bleeds on anticoagulation
• Low thrombotic risk:
  • AF with CHA₂DS₂-VASc ≤2
  • Unprovoked VTE > 12 months ago

Alternative Strategies:

• Left atrial appendage occlusion (LAAO): For AF patients with absolute contraindication to anticoagulation (e.g., recurrent ICH)
• IVC filter: For acute VTE with absolute contraindication to anticoagulation (temporary measure)
• Antiplatelet monotherapy: For very high bleeding risk + moderate thrombotic risk (inferior to anticoagulation but better than nothing)

DOAC Selection When Resuming:

• Consider switching agents if drug-specific factors contributed (e.g., rivaroxaban GI bleeding → switch to apixaban)
• Dose reduction: If appropriate per FDA labeling (e.g., apixaban 2.5mg BID if ≥2 of: age ≥80, weight ≤60kg, Cr ≥1.5)

---

Prognosis and Outcomes

Short-Term Outcomes (30-Day)

Mortality:

• All major DOAC bleeding: 9-13% at 30 days
• Intracranial hemorrhage: 30-45% at 30 days, 45-52% at 90 days
• GI bleeding (major): 5-7% at 30 days
• Retroperitoneal hemorrhage: 10-15% at 30 days

Predictors of Mortality (ICH):

• ICH Score (0-6 points):
  • "GCS 3-4: 2 points; 5-12: 1 point; 13-15: 0 points"
  • "Age ≥80: 1 point"
  • "ICH volume ≥30 cm³: 1 point"
  • "Intraventricular hemorrhage: 1 point"
  • "Infratentorial origin: 1 point"
• Interpretation: Score 0 = 0% mortality; Score 5-6 = 100% mortality at 30 days

Functional Outcomes (ICH):

• Modified Rankin Scale (mRS) at 90 days:
  • mRS 0-2 (functional independence): 20-30% of ICH survivors
  • mRS 3-5 (dependent): 40-50%
  • mRS 6 (death): 45-52%

Long-Term Outcomes

Recurrent Bleeding:

• After ICH: 2-5% per year (if anticoagulation resumed), 1-2% per year (if not resumed)
• After major GI bleeding: 10-15% per year (if underlying lesion not corrected)

Thrombotic Events After Bleeding:

• If anticoagulation held long-term: Stroke risk 4-8% per year (AF patients), VTE recurrence 10% per year
• Trade-off: Bleeding vs. thrombosis risk requires individualized assessment

Quality of Life:

• ICH survivors: Significant disability common (40-50% dependent for ADLs)
• GI bleeding: Usually returns to baseline if source treated

---

Special Populations

Chronic Kidney Disease (CKD)

Pharmacokinetic Considerations:

Bleeding Risk in CKD:

• 2-4x increased bleeding risk compared to normal renal function
• Uremic platelet dysfunction compounds DOAC effect
• Drug accumulation if dose not adjusted

Reversal Considerations:

• Dabigatran: Prolonged drug effect (half-life 28-34 hours if CrCl less than 30) → may require hemodialysis even after idarucizumab
• Factor Xa inhibitors: Less affected by renal function (use andexanet or PCC as usual)

Elderly Patients (Age ≥75)

Epidemiology:

• 60% of DOAC-treated patients are ≥75 years
• 2-3x higher bleeding risk vs. younger patients

Mechanisms of Increased Bleeding:

• Altered pharmacokinetics (↓ renal/hepatic clearance)
• Polypharmacy (drug interactions)
• Falls (ICH risk)
• Comorbidities (CKD, liver disease, thrombocytopenia)

Management Considerations:

• Lower threshold for reversal (even moderate bleeding may be life-threatening)
• Careful anticoagulation resumption discussion (goals of care, life expectancy)
• Consider dose-reduced regimens if appropriate

Liver Disease

Coagulopathy Complexity:

• Baseline coagulopathy (↓ synthesis of factors II, VII, IX, X, proteins C/S)
• Thrombocytopenia (hypersplenism, ↓ thrombopoietin)
• DOAC effect superimposed

DOAC Use in Liver Disease:

• Child-Pugh A: Generally safe (dose adjustments may not be needed)
• Child-Pugh B: Caution (consider dose reduction, avoid rivaroxaban)
• Child-Pugh C: Avoid DOACs (unpredictable pharmacokinetics, baseline coagulopathy)

Reversal:

• 4F-PCC may partially correct baseline coagulopathy + reverse DOAC
• Andexanet/idarucizumab work as usual, but baseline coagulopathy persists

Perioperative DOAC Bleeding

Planned Surgery/Procedure:

• Hold DOAC per half-life and bleeding risk:
  • "Low bleeding risk procedures: Hold 1-2 days (2-4 half-lives)"
  • "High bleeding risk procedures: Hold 2-4 days (4-5 half-lives)"
• Renal function guides timing (longer if CKD)

Emergency Surgery in DOAC-Bleeding Patient:

1. Determine time since last dose: If less than 12 hours, likely therapeutic levels
2. Reversal agent if life-threatening or high bleeding risk surgery
3. Delay surgery if possible (4-6 hours allows drug clearance if held, especially apixaban/rivaroxaban with shorter half-lives)
4. Surgical hemostasis critical (meticulous technique)

Neuraxial Anesthesia:

• Absolute contraindication if therapeutic DOAC levels
• Hold DOAC 48-96 hours before neuraxial procedure (depends on renal function, DOAC half-life)
• Spinal epidural hematoma risk if levels present

Pregnancy

DOAC Use: Contraindicated in pregnancy (cross placenta, teratogenic risk, fetal bleeding)

• Switch to LMWH or UFH if pregnancy planned/occurs

DOAC Bleeding in Pregnancy (e.g., unplanned pregnancy on DOAC):

• Treat as non-pregnant (reversal agents, supportive care)
• Fetal monitoring (potential fetal hemorrhage)
• Obstetrics consultation

---

Prevention and Risk Mitigation

Pre-Treatment Risk Assessment

HAS-BLED Score (0-9 points, ≥3 = high bleeding risk):

Interpretation:

• Score 0-2: Low risk (~1% bleeding/year)
• Score ≥3: High risk (~5-10% bleeding/year)
• Does NOT contraindicate anticoagulation (stroke risk usually higher), but guides monitoring and patient education

Modifiable Risk Factors

Optimize Before Starting DOAC:

1. Blood pressure control: Target less than 140/90 mmHg (reduces ICH risk)
2. Avoid unnecessary antiplatelets: Stop aspirin if no clear indication (e.g., primary prevention in AF patient)
3. PPI for GI protection: If high-risk GI features (prior ulcer, dual antiplatelet therapy)
4. Limit alcohol: less than 7 drinks/week (reduces falls, gastritis, thrombocytopenia)
5. Medication review: Avoid NSAIDs, minimize P-gp/CYP3A4 inhibitors

Patient Education:

• Recognize bleeding symptoms (red flags)
• Avoid contact sports, high-risk activities
• Medical alert bracelet/wallet card
• Inform all providers of anticoagulation

Monitoring (No Routine Labs, But...):

Situations Requiring Monitoring:

1. Renal function: Check CrCl annually (more often if CKD, age > 75)
   • Dabigatran: Check q6mo if CrCl 30-60
2. Hemoglobin: If bleeding symptoms (quantify blood loss)
3. Drug levels: NOT routine, but consider if:
   • Suspected overdose
   • Major bleeding (to guide reversal)
   • Extremes of weight (less than 50 kg or > 120 kg)
   • Drug interactions

---

Controversies and Evolving Evidence

Debate: Universal Reversal vs. Selective Reversal

Universal Reversal Advocates:

• Argument: All ICH/major bleeding should receive reversal (minimize hematoma expansion, improve outcomes)
• Evidence: RE-VERSE AD, ANNEXA-4 showed excellent hemostatic efficacy

Selective Reversal Advocates:

• Argument: Many bleeds minor, DOAC levels may be low (> 24h since dose), reversal expensive/thrombotic risk
• Evidence: Observational data show many patients do well without reversal if DOAC held and supportive care given

Current Consensus (ACC 2020, Anticoagulation Forum 2019):

• Life-threatening bleeding (ICH, major hemorrhage with instability): Strong recommendation for reversal
• Major bleeding (non-life-threatening): Consider reversal if high bleeding risk or ongoing bleeding
• Minor bleeding: Reversal NOT needed (hold DOAC, supportive care)

Andexanet Alfa: Efficacy vs. Thrombotic Risk

Concern: 10% thrombotic event rate at 30 days in ANNEXA-4

• Includes ischemic stroke (6%), MI (2%), VTE (6%)
• Mechanism: Restoration of procoagulant state + underlying thrombotic risk (AF, VTE) + no anticoagulation resumed immediately

Counter-argument:

• Most thrombotic events occurred in patients with high baseline thrombotic risk
• No comparator arm (unknown if higher/lower than supportive care alone)
• Mortality primarily driven by bleeding (14%), not thrombosis

Clinical Approach:

• Use andexanet for life-threatening bleeding (benefit likely outweighs thrombotic risk)
• Resume anticoagulation as soon as safe (balance bleeding vs. thrombosis)
• Consider thromboprophylaxis (LMWH) bridge if prolonged time off anticoagulation

PCC vs. Andexanet: Cost-Effectiveness

Andexanet: ~$50,000 per dose 4F-PCC: ~$3,000-5,000 per dose

Questions:

• Is 10-fold cost justified by superior efficacy?
• No head-to-head trial (PCC vs. andexanet)
• Observational data suggest similar hemostatic outcomes

Institutional Approaches:

• Some restrict andexanet to ICH only (use PCC for GI/other bleeding)
• Some use PCC first-line due to cost, reserve andexanet for failures
• Guidelines recommend andexanet first-line if available (acknowledging cost as barrier)

Optimal Timing to Resume Anticoagulation After ICH

Observational Data:

• Resuming anticoagulation after ICH: ↑ ischemic stroke protection, ↑ recurrent ICH risk
• "Sweet spot": 4-8 weeks after ICH (some data suggest ~30 days optimal)

Ongoing Trials:

• APACHE-AF: Apixaban vs. avoid anticoagulation after ICH in AF patients (results pending)
• SoSTART: Timing of anticoagulation resumption after ICH (results 2022 - suggested starting AC after ICH may reduce risk of thrombosis without increasing ICH recurrence, but underpowered)

Current Practice: Case-by-case, multidisciplinary decision (neurology, cardiology, patient preferences)

---

Viva Questions and Answers

Question 1: How does dabigatran differ from rivaroxaban in terms of reversal strategy?

Answer: Dabigatran is a direct thrombin inhibitor, while rivaroxaban is a factor Xa inhibitor. They have different specific reversal agents:

• Dabigatran: Reversed by idarucizumab (Praxbind), a humanized monoclonal antibody fragment that binds dabigatran with 350-fold higher affinity than thrombin. Dose is 5g IV (two 2.5g vials), providing immediate and complete reversal. Dabigatran is also dialyzable (35% protein bound) - hemodialysis can remove 50-60% in 4 hours if idarucizumab unavailable.

• Rivaroxaban: Reversed by andexanet alfa (Andexxa), a modified recombinant factor Xa that acts as a decoy to sequester rivaroxaban. Dosing is weight/dose-dependent (400mg or 800mg bolus, followed by infusion). Andexanet has a short half-life, so rebound anticoagulation is possible. Alternative is 4-factor PCC (50 units/kg), which non-specifically bypasses factor Xa inhibition.

Key difference: Idarucizumab is highly specific and provides sustained reversal, while andexanet requires continuous infusion and has thrombotic risk (~10% at 30 days).

Question 2: A 78-year-old on apixaban 5mg BID presents with intracerebral hemorrhage 6 hours after last dose. CT shows 35 mL basal ganglia ICH. How do you manage this patient?

Answer: This is a life-threatening emergency requiring immediate reversal:

Immediate (0-15 minutes):

1. ABCDE assessment: Secure airway if GCS less than 8, IV access, vitals
2. Hold apixaban immediately
3. Activate neurosurgery and pharmacy (for andexanet alfa)
4. Blood pressure control: Target SBP 140-160 mmHg (IV labetalol or nicardipine)
5. Labs: STAT CBC, BMP (renal function), PT/aPTT, type & screen, anti-Xa level (if available)

Reversal (15-60 minutes):

• Andexanet alfa HIGH DOSE (apixaban 5mg less than 8 hours ago):
  • 800mg IV bolus over 30 min, then 8 mg/min × 120 min
• Alternative if andexanet unavailable: 4F-PCC 50 units/kg IV

Supportive:

• Platelet transfusion if less than 100,000/μL (target > 100,000 for ICH)
• Avoid: Platelet transfusion if platelet count normal (no proven benefit)
• Serial neurological exams: q1-2h
• Repeat CT head at 6-24 hours (assess for expansion)

Disposition:

• Neuro ICU admission
• Neurosurgery evaluation (35 mL ICH in basal ganglia - likely medical management, but case-by-case)

Anticoagulation resumption: Discuss at 4-8 weeks (neurology, cardiology, patient). Consider CHA₂DS₂-VASc score vs. ICH recurrence risk.

Question 3: What laboratory tests can you use to assess dabigatran levels, and how do you interpret them?

Answer: Several tests available, with varying sensitivity and utility:

Screening Tests (Qualitative):

1. aPTT:

   • Prolonged (1.5-3x normal) at therapeutic dabigatran levels
   • Normal aPTT: Likely excludes clinically significant dabigatran (but not 100% sensitive)
   • Variable sensitivity depending on reagent

2. Thrombin Time (TT):

   • Very sensitive to dabigatran (most sensitive screening test)
   • Normal TT: Excludes dabigatran effect (high negative predictive value)
   • Prolonged TT: Dabigatran present, but not quantitative

Quantitative Tests (if available): 3. Dilute Thrombin Time (dTT) or Hemoclot assay:

• Linear relationship with dabigatran concentration
• Interpretation:
  • less than 50 ng/mL: Minimal/no effect (safe for surgery)
  • 50-200 ng/mL: Therapeutic range

  • 200 ng/mL: Supratherapeutic (consider reversal if bleeding)

• Gold standard for dabigatran quantification

4. Ecarin Clotting Time (ECT):
   • Direct measure of thrombin inhibition
   • Less widely available than dTT

Clinical Application:

• Emergency setting: Start with aPTT and TT (rapid, available)
  • Normal TT → no reversal needed
  • Prolonged TT → send dTT (if available), consider reversal if life-threatening bleeding
• Planned surgery: dTT level to guide safety of proceeding

Pitfall: PT/INR is not sensitive to dabigatran (may be normal or only mildly prolonged at therapeutic levels).

Question 4: What is the evidence for tranexamic acid in DOAC-associated bleeding?

Answer: There is no direct RCT evidence for TXA specifically in DOAC-associated bleeding. Evidence is extrapolated from other bleeding contexts:

Supporting Evidence (other indications):

1. CRASH-2 (trauma): 20,211 patients, TXA (1g bolus + 1g over 8h) reduced all-cause mortality (RR 0.91, 95% CI 0.85-0.97) and death from bleeding (RR 0.85, 95% CI 0.76-0.96). Benefit greatest if given less than 3 hours from injury.

2. WOMAN trial (postpartum hemorrhage): 20,060 women, TXA reduced death from bleeding (RR 0.81, 95% CI 0.65-1.00).

3. HALT-IT (acute GI bleeding): 12,009 patients, TXA did NOT reduce mortality and possibly increased thrombotic events. Questioned utility in GI bleeding.

Theoretical Rationale for DOAC Bleeding:

• TXA inhibits plasminogen activation → prevents clot breakdown
• Complements DOAC reversal (DOACs prevent clot formation, TXA prevents clot lysis)

Current Practice:

• Consider TXA in massive DOAC-associated bleeding requiring transfusion (especially trauma-related)
• Avoid if recent thrombotic event (less than 24h), seizure history (TXA may ↑ seizure risk in ICH)
• Dose: 1g IV over 10 min, then 1g over 8 hours (CRASH-2 regimen)

Guideline Recommendations:

• ACC 2020, Anticoagulation Forum 2019: No specific recommendation (insufficient evidence, may consider in massive bleeding)

Bottom Line: TXA is a reasonable adjunct in life-threatening DOAC bleeding, but reversal agents and supportive care remain mainstays.

Question 5: When would you choose 4F-PCC over andexanet alfa for factor Xa inhibitor reversal?

Answer: Several scenarios favor 4F-PCC (Kcentra) over andexanet alfa:

Practical Considerations:

1. Andexanet unavailable:

   • Not stocked at institution (very expensive, limited shelf-life)
   • Out of stock / supply chain issues
   • Approval delay (some hospitals require special authorization)

2. Cost constraints:

   • Andexanet ~$50,000 vs. PCC ~$3,000-5,000
   • Some institutions restrict andexanet to ICH only, use PCC for GI/other bleeding

3. Time-sensitive situations:

   • PCC faster to prepare/administer (~20-30 min infusion)
   • Andexanet requires 2-hour infusion (bolus + continuous infusion)
   • If emergent surgery needed less than 1 hour, PCC may be more practical

Clinical Scenarios: 4. Non-life-threatening major bleeding:

• Stable GI bleeding (not exsanguinating)
• Guidelines support either agent; PCC reasonable first-line

5. Uncertain DOAC type/level:
   • If unable to confirm which factor Xa inhibitor, PCC works for all
   • If > 24 hours since last dose (low levels expected), PCC may suffice

Evidence Considerations:

• No head-to-head trial comparing PCC vs. andexanet
• Observational data suggest similar hemostatic efficacy (though andexanet RCT shows 82% excellent/good hemostasis)
• PCC thrombotic risk 0.9-1.8% vs. andexanet 10% (but different patient populations)

Guideline Stance:

• ACC 2020, Anticoagulation Forum 2019: Prefer andexanet if available (higher quality evidence from ANNEXA-4)
• PCC is acceptable alternative if andexanet unavailable (off-label, lower evidence quality)

Bottom Line: For ICH or life-threatening hemorrhage with factor Xa inhibitor, andexanet is first-line if available. For non-life-threatening bleeding or resource constraints, PCC (50 units/kg) is a reasonable alternative. Both are superior to FFP alone.

---

Key Learning Points

Critical Actions (Emergency Department)

1. Identify the specific DOAC (dabigatran vs. rivaroxaban vs. apixaban vs. edoxaban) - determines reversal strategy
2. Time since last dose - if > 24-48 hours, drug effect minimal (unless renal impairment)
3. Immediate reversal for life-threatening bleeding (ICH, hemodynamic instability)
   • Dabigatran → Idarucizumab 5g IV
   • Factor Xa inhibitor → Andexanet alfa (dose-dependent) or 4F-PCC 50 units/kg
4. Supportive care remains essential (transfusion, source control, hemodynamic support)
5. Anticoagulation resumption is a multidisciplinary decision (not automatic)

Common Pitfalls

1. Assuming normal PT/aPTT excludes therapeutic DOAC levels - DOACs have variable effects on coags; drug-specific assays needed for quantification
2. Giving FFP alone for DOAC reversal - insufficient factor concentrations, ineffective
3. Delaying reversal while awaiting drug levels - treat empirically if life-threatening bleeding
4. Resuming anticoagulation too early after ICH - balance thrombotic vs. bleeding risk, typically 4-8 weeks minimum
5. Using 3-factor PCC instead of 4-factor PCC - inferior (lacks factor VII)

High-Yield Facts (Exam Preparation)

1. Dabigatran is the only DOAC that is dialyzable (35% protein bound)
2. Idarucizumab binds dabigatran with 350x higher affinity than thrombin
3. Andexanet alfa is a modified factor Xa decoy (lacks enzymatic activity)
4. RE-VERSE AD trial: 89% complete reversal with idarucizumab
5. ANNEXA-4 trial: 82% excellent/good hemostasis with andexanet, but 10% thrombotic events
6. 4F-PCC dose: 25-50 units/kg (based on factor IX content)
7. TXA in trauma: 1g IV bolus + 1g over 8h (CRASH-2 regimen), most effective if less than 3h from injury
8. ICH hematoma expansion: Occurs in 30-40% within 24 hours - reversal urgency critical
9. HAS-BLED score ≥3: High bleeding risk (~5-10%/year), but NOT a contraindication to anticoagulation
10. Rivaroxaban has highest GI bleeding risk among DOACs (20mg once daily formulation)

---

References

1. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med. 2017;377(5):431-441. doi:10.1056/NEJMoa1707278

2. Connolly SJ, Crowther M, Eikelboom JW, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2019;380(14):1326-1335. doi:10.1056/NEJMoa1814051

3. Cuker A, Burnett A, Triller D, et al. Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. Am J Hematol. 2019;94(6):697-709. doi:10.1002/ajh.25475

4. Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;76(5):594-622. doi:10.1016/j.jacc.2020.04.053

5. Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612-1676. doi:10.1093/europace/euab065

6. Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: Executive Summary. A Statement for Healthcare Professionals From the Neurocritical Care Society and the Society of Critical Care Medicine. Crit Care Med. 2016;44(12):2251-2257. doi:10.1097/CCM.0000000000002057

7. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-962. doi:10.1016/S0140-6736(13)62343-0

8. Dobesh PP, Fanikos J. New oral anticoagulants for stroke prevention in atrial fibrillation. Ther Clin Risk Manag. 2014;10:685-699. doi:10.2147/TCRM.S52143

9. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med. 2015;373(9):823-833. doi:10.1056/NEJMoa1501035

10. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med. 2015;373(25):2413-2424. doi:10.1056/NEJMoa1510991

11. Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14(3):623-627. doi:10.1111/jth.13227

12. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467-1507. doi:10.1093/europace/euv309

13. Roberts LN, Demetriou CA, Arya R. Multicentre comparison of the coagulation effects of apixaban, dabigatran, rivaroxaban, and edoxaban: the ACTION study. Thromb Res. 2018;165:35-41. doi:10.1016/j.thromres.2018.03.012

14. CRASH-2 trial collaborators, Shakur H, Roberts I, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23-32. doi:10.1016/S0140-6736(10)60835-5

15. WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105-2116. doi:10.1016/S0140-6736(17)30638-4

16. Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015;46(7):2032-2060. doi:10.1161/STR.0000000000000069

17. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. doi:10.1056/NEJMoa1107039

18. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891. doi:10.1056/NEJMoa1009638

19. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-2104. doi:10.1056/NEJMoa1310907

20. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151. doi:10.1056/NEJMoa0905561

21. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-2352. doi:10.1056/NEJMoa0906598

22. Raval AN, Cigarroa JE, Chung MK, et al. Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association. Circulation. 2017;135(10):e604-e633. doi:10.1161/CIR.0000000000000477

---

Version History

---

Document Statistics:

• Total Lines: 1,285
• Word Count: ~11,500
• Reading Time: 42-45 minutes
• Evidence Level: A (Multiple high-quality RCTs, meta-analyses, expert consensus)
• Target Audience: Emergency medicine physicians, intensivists, hematologists, internists preparing for MRCP/FRCEM/FRACP